Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer.

Ma P, Rahima Benhabbour S, Feng L, Mumper RJ.

Cancer Lett. 2013 Jul 1;334(2):253-62. doi: 10.1016/j.canlet.2012.08.009.

2.

2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model.

Peng L, Schorzman AN, Ma P, Madden AJ, Zamboni WC, Benhabbour SR, Mumper RJ.

Int J Nanomedicine. 2014 Jul 30;9:3601-10. doi: 10.2147/IJN.S66040.

3.

Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.

Latimer P, Menchaca M, Snyder RM, Yu W, Gilbert BE, Sanders BG, Kline K.

Exp Biol Med (Maywood). 2009 Oct;234(10):1244-52. doi: 10.3181/0901-RM-8.

PMID:
19657067
4.

Superior intratumoral penetration of paclitaxel nanodots strengthens tumor restriction and metastasis prevention.

Ni D, Ding H, Liu S, Yue H, Bao Y, Wang Z, Su Z, Wei W, Ma G.

Small. 2015 Jun 3;11(21):2518-26. doi: 10.1002/smll.201403632.

PMID:
25678130
5.

In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.

Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, Seo MH.

J Control Release. 2001 May 14;72(1-3):191-202.

PMID:
11389998
6.

Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts.

Shanmugam S, Park JH, Chi SC, Yong CS, Choi HG, Woo JS.

Int J Pharm. 2011 Jan 17;403(1-2):130-5. doi: 10.1016/j.ijpharm.2010.10.033.

PMID:
20974239
7.

Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations.

Al-Ghananeem AM, Malkawi AH, Muammer YM, Balko JM, Black EP, Mourad W, Romond E.

AAPS PharmSciTech. 2009;10(2):410-7. doi: 10.1208/s12249-009-9222-5.

8.
9.

Solid lipid nanoparticles of anticancer drugs against MCF-7 cell line and a murine breast cancer model.

Zhuang YG, Xu B, Huang F, Wu JJ, Chen S.

Pharmazie. 2012 Nov;67(11):925-9.

PMID:
23210242
10.

Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration.

Lv PP, Wei W, Yue H, Yang TY, Wang LY, Ma GH.

Biomacromolecules. 2011 Dec 12;12(12):4230-9. doi: 10.1021/bm2010774.

PMID:
22044456
11.

Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.

Lu J, Chuan X, Zhang H, Dai W, Wang X, Wang X, Zhang Q.

Int J Pharm. 2014 Aug 25;471(1-2):525-35. doi: 10.1016/j.ijpharm.2014.05.032.

PMID:
24858391
12.

Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy.

Sharma D, Chelvi TP, Kaur J, Chakravorty K, De TK, Maitra A, Ralhan R.

Oncol Res. 1996;8(7-8):281-6.

PMID:
8938791
13.

Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992).

Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR.

J Control Release. 2007 Jan 22;117(1):40-50.

PMID:
17126446
14.

Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity.

Liang L, Lin SW, Dai W, Lu JK, Yang TY, Xiang Y, Zhang Y, Li RT, Zhang Q.

J Control Release. 2012 Jun 28;160(3):618-29. doi: 10.1016/j.jconrel.2012.02.020.

PMID:
22410114
15.

Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.

Zhang X, Chen J, Kang Y, Hong S, Zheng Y, Sun H, Xu C.

Int J Pharm. 2013 Sep 10;453(2):498-505. doi: 10.1016/j.ijpharm.2013.06.038.

PMID:
23811008
16.

Shrapnel nanoparticles loading docetaxel inhibit metastasis and growth of breast cancer.

Xu P, Meng Q, Sun H, Yin Q, Yu H, Zhang Z, Cao M, Zhang Y, Li Y.

Biomaterials. 2015 Sep;64:10-20. doi: 10.1016/j.biomaterials.2015.06.017.

PMID:
26106797
17.

Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation.

Zhao P, Wang H, Yu M, Liao Z, Wang X, Zhang F, Ji W, Wu B, Han J, Zhang H, Wang H, Chang J, Niu R.

Eur J Pharm Biopharm. 2012 Jun;81(2):248-56. doi: 10.1016/j.ejpb.2012.03.004.

PMID:
22446630
18.

Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.

Bai F, Wang C, Lu Q, Zhao M, Ban FQ, Yu DH, Guan YY, Luan X, Liu YR, Chen HZ, Fang C.

Biomaterials. 2013 Aug;34(26):6163-74. doi: 10.1016/j.biomaterials.2013.04.062.

PMID:
23706689
19.

Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.

Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD.

Int J Pharm. 2007 Jun 29;338(1-2):317-26.

PMID:
17368984
20.

Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.

Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK, Kim DD.

Pharm Res. 2007 Dec;24(12):2402-11.

PMID:
17828616

Supplemental Content

Support Center